CN1561338A - 作为5－羟基色胺－6配体的苯并二氢吡喃衍生物 - Google Patents

作为5－羟基色胺－6配体的苯并二氢吡喃衍生物 Download PDF

Info

Publication number
CN1561338A
CN1561338A CNA028193342A CN02819334A CN1561338A CN 1561338 A CN1561338 A CN 1561338A CN A028193342 A CNA028193342 A CN A028193342A CN 02819334 A CN02819334 A CN 02819334A CN 1561338 A CN1561338 A CN 1561338A
Authority
CN
China
Prior art keywords
methyl
amino
dihydro
chromene
benzsulfamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028193342A
Other languages
English (en)
Chinese (zh)
Inventor
L·P·格林布拉特
M·G·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1561338A publication Critical patent/CN1561338A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
CNA028193342A 2001-10-04 2002-09-30 作为5－羟基色胺－6配体的苯并二氢吡喃衍生物 Pending CN1561338A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32695701P 2001-10-04 2001-10-04
US60/326,957 2001-10-04

Publications (1)

Publication Number Publication Date
CN1561338A true CN1561338A (zh) 2005-01-05

Family

ID=23274503

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028193342A Pending CN1561338A (zh) 2001-10-04 2002-09-30 作为5－羟基色胺－6配体的苯并二氢吡喃衍生物

Country Status (8)

Country Link
US (1) US6706757B2 (cg-RX-API-DMAC10.html)
EP (1) EP1432696A1 (cg-RX-API-DMAC10.html)
JP (1) JP2005505586A (cg-RX-API-DMAC10.html)
CN (1) CN1561338A (cg-RX-API-DMAC10.html)
BR (1) BR0213094A (cg-RX-API-DMAC10.html)
CA (1) CA2461381A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA04003087A (cg-RX-API-DMAC10.html)
WO (1) WO2003029238A1 (cg-RX-API-DMAC10.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
RU2372344C2 (ru) * 2004-05-05 2009-11-10 Ф. Хоффманн-Ля Рош Аг Арилсульфонилбензодиоксаны, применяемые для модуляции 5-нт6 рецептора, 5-нт2a рецептора или и того, и другого
AU2005291541B2 (en) * 2004-09-30 2011-03-10 F. Hoffmann-La Roche Ag Benzoxazine and quinoxaline derivatives and uses
EP1799306B1 (en) * 2004-09-30 2011-02-23 F. Hoffmann-La Roche AG Compositions and methods for treating cognitive disorders
EP2439203B1 (en) * 2004-10-14 2014-11-19 AbbVie Deutschland GmbH & Co KG Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
CN101119965B (zh) * 2004-12-21 2012-09-26 弗·哈夫曼-拉罗切有限公司 萘满和茚满衍生物及其用途
KR20070088798A (ko) * 2004-12-21 2007-08-29 에프. 호프만-라 로슈 아게 크로만 유도체 및 그의 5-ｈｔ 수용체 리간드로서의 용도
KR100899061B1 (ko) * 2004-12-21 2009-05-25 에프. 호프만-라 로슈 아게 테트랄린 및 인단 유도체 및 이의 용도
ATE409179T1 (de) * 2004-12-21 2008-10-15 Hoffmann La Roche Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
CN101198322A (zh) * 2005-04-22 2008-06-11 惠氏公司 用于治疗或预防抑郁症的新治疗组合
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
AR054044A1 (es) * 2005-05-23 2007-05-30 Astrazeneca Ab Derivados de cromano y tetrahidronaftaleno como moduladores del receptor 5 - ht6; intermediarios en su preparacion; composiciones farmaceuticas que los contienen y su empelo en la fabricacion de medicamentos para el tratamiento de enfermedades del snc y de la obesidad.
AR054363A1 (es) * 2005-05-23 2007-06-20 Astrazeneca Ab Compuestos que exhiben actividad moduladora en el receptor 5-hidroxi-triptamina 6
CN101300246A (zh) * 2005-11-03 2008-11-05 弗·哈夫曼-拉罗切有限公司 作为5－ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物
JP2009541249A (ja) * 2006-06-20 2009-11-26 エフ．ホフマン−ラ ロシュ アーゲー アリールスルホニルナフタレン誘導体およびその使用
WO2007147762A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
MX2008015843A (es) * 2006-06-20 2009-01-09 Hoffmann La Roche Derivados de tetralina e indano y usos de los mismos.
CL2007003044A1 (es) * 2006-10-24 2008-07-04 Wyeth Corp Compuestos derivados de benzoxazina; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y abuso o dependencia de sustancias entre otros.
TW200831478A (en) * 2006-10-25 2008-08-01 Wyeth Corp Chromane derivatives, synthesis thereof, and intermediates thereto
MX2010011724A (es) 2008-04-29 2010-11-30 Nsab Af Neurosearch Sweden Ab Moduladores de neurotransmision de dopamina.
WO2009133110A1 (en) 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135474A1 (de) * 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
EP0655448B1 (en) * 1992-08-17 2000-04-12 Chugai Seiyaku Kabushiki Kaisha Benzopyran and benzoxazine derivatives
US6448269B1 (en) * 1993-07-22 2002-09-10 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
GB9316111D0 (en) * 1993-08-04 1993-09-22 Pfizer Ltd Benzopyrans
ATE256130T1 (de) * 1993-08-19 2003-12-15 Janssen Pharmaceutica Nv Gefässverengende dihydrobenzopyranderivate
US5663194A (en) * 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
US6191164B1 (en) * 1996-05-15 2001-02-20 Hoechst Aktiengesellschaft Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
KR100499106B1 (ko) * 1996-12-10 2005-07-01 브리스톨-마이어즈 스퀴브 컴페니 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6051586A (en) * 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
CA2314925A1 (en) * 1997-12-19 1999-07-01 Bayer Corporation Novel sulfonamide substituted chroman derivatives useful as beta-3 adrenoreceptor agonists
GB9813949D0 (en) * 1998-06-29 1998-08-26 Smithkline Beecham Plc Novel compounds
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
FR2787789B1 (fr) * 1998-12-29 2002-06-14 Lipha Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
ES2250196T3 (es) * 1999-08-26 2006-04-16 Aventis Pharmaceuticals Inc. Aminoiminometil o aminometil dihidrobenzofuranos y benzopiranos sustituidos.
WO2001021610A1 (en) * 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6323238B1 (en) * 1999-10-21 2001-11-27 Dongbu Hannong Chemical Co., Ltd. Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
JP2005505586A (ja) 2005-02-24
WO2003029238A1 (en) 2003-04-10
US6706757B2 (en) 2004-03-16
EP1432696A1 (en) 2004-06-30
BR0213094A (pt) 2004-10-13
US20030158175A1 (en) 2003-08-21
CA2461381A1 (en) 2003-04-10
MXPA04003087A (es) 2004-09-06

Similar Documents

Publication Publication Date Title
CN1222511C (zh) 作为5－羟色胺－6配体的1－芳基－或1－烷基磺酰基－杂环基吲哚
CN1150166C (zh) Cb2受体拮抗剂化合物
CN1273450C (zh) 作为5－羟色胺－6配体的1－芳基或1－烷基磺酰基吲哚衍生物
CN1281605C (zh) 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
CN1234688C (zh) 3－芳酰基吲哚及其作为cb2受体激动剂的应用
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1771244A (zh) 作为5－羟色胺－6配体的杂环－3－磺酰基吲唑
CN1620455A (zh) 作为5－羟色胺－6配体的氮杂吲哚基烷基胺衍生物
CN1871236A (zh) 用于治疗5－HT6受体相关病症的新的四氢螺{哌啶－2,7′－吡咯并[3,2－b]吡啶}衍生物和新的吲哚衍生物
CN1678306A (zh) 在炎性、变应性和增生性疾病中用作糖皮质激素模拟物的3－(磺酰氨基乙基)－吲哚衍生物
CN1390217A (zh) 二环和三环杂芳族化合物
CN1701068A (zh) 新颖的化合物和它们的用途
CN1400973A (zh) 新的联芳基甲酰胺
CN1394203A (zh) 用作5－ht2a受体拮抗剂的哌啶和哌嗪衍生物
CN1694879A (zh) 具有激酶抑制活性的异喹啉衍生物和包含异喹啉衍生物的药剂
CN1538968A (zh) 新型化合物
CN1553916A (zh) 用作gabaa受体配体的杂芳基取代的稠合双环杂芳基化合物
CN1662539A (zh) 用作抗精神病和抗肥胖药物的[1,4]二氮杂芳辛并[7,8,1－hi]吲哚衍生物
CN1372547A (zh) 用于治疗中枢神经系统疾病的氨基烷氧基咔唑
CN1492863A (zh) 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
CN1620290A (zh) 作为5－羟色胺－6配体的吲哚基烷基胺衍生物
JP2005505586A (ja) ５−ヒドロキシトリプタミン−６リガンドとしてのクロマン誘導体
CN1832740A (zh) 吲哚－5磺酰胺衍生物及其制备和其作为5－ht－6调节剂的用途
CN1310909C (zh) 新型杂芳基衍生物、其制备以及应用
CN1934081A (zh) 新型(亚)苄基－内酰胺衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication